Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q32 Bio Inc. Director's Dealing 2023

Mar 16, 2023

34891_dirs_2023-03-16_cc8421a4-d20b-4d5f-a131-782d3ae20506.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-03-07

Reporting Person: Jordan Julie (Chief Medical Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2519 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Stock Option (Right to Buy) $6.53 2031-06-02 Common Stock (65000) Direct
Employee Stock Option (Right to Buy) $2.71 2032-02-24 Common Stock (56000) Direct
Employee Stock Option (Right to Buy) $3.59 2032-03-02 Common Stock (9000) Direct
Employee Stock Option (Right to Buy) $1.60 2033-02-23 Common Stock (143000) Direct
Restricted Stock Units $ Common Stock (350) Direct
Restricted Stock Units $ Common Stock (5360) Direct
Restricted Stock Units $ Common Stock (1340) Direct
Restricted Stock Units $ Common Stock (24000) Direct

Footnotes

F1: The option vests or has vested as to 25% of the underlying shares on May 3, 2022 and in 36 substantially equal monthly installments upon the Reporting Person's completion of each full month of service thereafter so that such option will become fully vested on May 3, 2025.

F2: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.

F3: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.

F4: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023 so that such option will become fully vested on January 1, 2027.

F5: The restricted stock units will vest and settle in full on August 2, 2023.

F6: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.

F7: The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.

F8: The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.

F9: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.